Projects per year
Personal profile
Biography
- Head, Servier Program in Drug Discovery
- Faculty of Pharmacy and Pharmaceutical Sciences
- Monash Institute of Pharmaceutical Sciences
Chris Langmead has a strong interest in drug discovery, having spent 15 years working in the pharmaceutical and biotech industry in the UK, where he led project teams to discover four pre-clinical candidate drugs and managed collaborations with academic labs and other pharmaceutical companies.
In 2012 he joined MIPS to head up a drug discovery program in collaboration with Servier Laboratories, France. He is particularly interested in GPCRs as drug targets in neurodegenerative and psychiatric disorders, but also has interest in structure-function of GPCRs and analytical receptor pharmacology, with particular reference to allosteric interactions.
In 2012 he joined MIPS to head up a drug discovery program in collaboration with Servier Laboratories, France. He is particularly interested in GPCRs as drug targets in neurodegenerative and psychiatric disorders, but also has interest in structure-function of GPCRs and analytical receptor pharmacology, with particular reference to allosteric interactions.
Servier Program in Drug Discovery
In 2012, the Monash Institute of Pharmaceutical Sciences (MIPS) entered into a collaborative drug discovery research agreement with Les Laboratoires Servier, a leading European pharmaceutical company (http://tinyurl.com/brrztb4).
The collaboration makes use of MIPS' acknowledged world-leading capability in the identification of novel GPCR targets, in the understanding of GPCR functional biology and in the design of new chemical entities to modulate GPCR activity. MIPS has developed GPCR expertise comprising technology, research facilities and world leading scientists that enable it to conduct fundamental research, drug discovery and preclinical drug development activities on GPCR targets with therapeutic potential.
Monash teaching commitment
- Lectures to 3rd year BPharmSci students in the Faculty of Pharmacy and Pharmaceutical Sciences
- Supervision of Honours students in Drug Discovery Biology
Research interests
- GPCR target validation, hit identification and lead optimisation
- CNS drug discovery
- Allosteric modulation of GPCRs
- Molecular and analytical pharmacology
Research area keywords
- G protein-coupled receptors
- drug discovery
- hit identification
- high throughput screening
- muscarinic receptors
- neuropharmacology
- analytical pharmacology
- allosteric modulation
- structure-function
- target validation
- hit-to-lead
- lead optimisation
- psychiatric disorders
- cognitive disorders
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2016 2020
Alcohol and Striatal Adaptation
Lawrence, A., Langmead, C. & Spanswick, D.
National Health & Medical Research Council (NHMRC)
1/01/17 → 31/12/20
Project: Research
NHMRC Equipment Grant - FLIPR Tetra high-throughput cellular screening system
Sexton, P., Christopoulos, A., Leach, K., Gregory, K., Veldhuis, N., Poole, D. & Langmead, C.
1/01/18 → 31/12/18
Project: Research
GPR88 as a novel target for fronto-striatal dysfunction in schizophrenia
Langmead, C. & Nithianantharajah, J.
National Health & Medical Research Council (NHMRC)
1/01/16 → 31/12/18
Project: Research
Research Output 2001 2019
Bone marrow transplantation and RNAseq analysis of Gpr21−/− monocytes reveals reduced migratory function and downregulation of inflammatory genes
Riddy, D., Kammoun, H., Bosnyak-Gladovic, S., Ziemann, M., Summers, R., Sexton, P. M., Murphy, A. J. M. & Langmead, C., 2019. 2 p.Research output: Contribution to conference › Abstract › Other
Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists
Riddy, D. M., Cook, A. E., Shackleford, D. M., Pierce, T. L., Mocaer, E., Mannoury la Cour, C., Sors, A., Charman, W. N., Summers, R. J., Sexton, P. M., Christopoulos, A. & Langmead, C. J., 1 Jan 2019, In : Neuropharmacology. 144, p. 244-255 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes S
Bradley, S. J., Molloy, C., Bundgaard, C., Mogg, A. J., Thompson, K. J., Dwomoh, L., Sanger, H. E., Crabtree, M. D., Brooke, S. M., Sexton, P. M., Felder, C. C., Christopoulos, A., Broad, L. M., Tobin, A. B. & Langmead, C. J., 1 Jun 2018, In : Molecular Pharmacology. 93, 6, p. 645-656 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research
Riddy, D. M., Goy, E., Delerive, P., Summers, R. J. & Langmead, C. J., 1 May 2018, In : PLoS ONE. 13, 5, 19 p., e0197177.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold
Bender, A. M., Cho, H. P., Nance, K. D., Lingenfelter, K. S., Luscombe, V. B., Gentry, P. R., Voigtritter, K., Berizzi, A. E., Sexton, P. M., Langmead, C. J., Christopoulos, A., Locuson, C. W., Bridges, T. M., Chang, S., O'Neill, J. C., Zhan, X., Niswender, C. M., Jones, C. K., Conn, P. J. & Lindsley, C. W., 18 Jul 2018, In : ACS Chemical Neuroscience. 9, 7, p. 1572-1581 10 p.Research output: Contribution to journal › Article › Research › peer-review